This article is more than 5 years old. Information may no longer be current.
Phase 1 trial for Graves’ disease treatment begins
Click Here to Manage Email Alerts
Apitope has enrolled the first patient in a phase 1 clinical trial of its novel peptide therapy for the treatment of Graves’ disease, according to a company press release.
Graves’ disease is an autoimmune disorder that affects over 5 million people worldwide. Currently, there is no cure, and treatment options have limited efficacy.
Apitope’s therapy, ATX-GD-59, attempts to treat and prevent the production of stimulating antibodies against the thyroid-stimulating hormone receptor, which leads to Graves’ disease.
“This is the first new therapy for Graves’ disease to be tested in over 50 years and is a significant step forward in the development of the drug,” Simon Pearce, MD, professor of endocrinology at Newcastle University, said in the release. “We are very pleased to be leading the first clinical trial of ATX-GD-59, which has significant potential to treat the underlying cause of this condition for the first time.”
The trial will enroll 30 patients.